Teva- Pharmaceutical Industries Ltd. TEVA

NYS: TEVA | ISIN: US8816242098   21/10/2025
18,99 USD (-2,21%)
(-2,21%)   21/10/2025
Grafiek Teva- Pharmaceutical Industries Ltd. Grafiek Teva- Pharmaceutical Industries Ltd.
woensdag 5 november 2025, 13:00
Kwartaalcijfers (3de kwartaal)

Teva- Pharmaceutical Industries Ltd. in het nieuws

21 oktober 2025 · Teva et Prestige Biopharma concluent un accord de licence pour la commercialisation de Tuznue® en Europe · Persbericht

20 oktober 2025 · Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe · Persbericht

10 oktober 2025 · FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder · Persbericht

1 oktober 2025 · Europese Commissie opent mededingingsonderzoek naar griepvaccins bij Sanofi · Bolero.be

Sanofi bevestigt dat de Europese mededingingsautoriteiten invallen hebben gedaan in kantoren in Frankrijk en Duitsland. De Europese Commissie onderzoekt mogelijke misleidende communicatie over concurrenten in de griepvaccinmarkt,...

25 september 2025 · Teva Releases Q3 2025 Aide Memoire · Persbericht

25 september 2025 · Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 · Persbericht

21 september 2025 · Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction · Persbericht

21 september 2025 · New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed · Persbericht

16 september 2025 · Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting · Persbericht

9 september 2025 · Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy · Persbericht

Profiel Teva- Pharmaceutical Industries Ltd.

Fabricage van farmaceutische preparaten
Farmaceutische Producten: Generisch
Gezondheidstechnologie
Productie

Mijn selecties